Theriva Biologics gets FDA guidance for a Phase 3 study on its pancreatic cancer drug VCN-01.
Theriva Biologics has received guidance from the U.S. FDA on the design of its Phase 3 study for VCN-01, a potential treatment for metastatic pancreatic cancer. The company will use this guidance to advance the clinical trial aimed at evaluating the efficacy and safety of the drug for this deadly disease.
December 05, 2024
3 Articles